SOURCE: PetAirapy

PetAirapy Logo

November 09, 2010 12:37 ET

Lab Tests Confirm Unparalleled Kill Rates; Proprietary PetAirapy™ UVGI Technology Wipes Parvo Virus in 60 Seconds

"I love this unit and I tell you what, this is something I would recommend for my clients at the veterinarian hospital!" Says Dr. Marty Becker Showcasing PetAirapy as the Emerging Leader in Ultraviolet Germicidal Solutions on ABC News Now

ST. CHARLES, IL--(Marketwire - November 9, 2010) -  PetAirapy, the company seen on ABC News Now and featured in Veterinary Practice News, today unveiled pioneering research results regarding products equipped with its proprietary UVGI technology.

The study was performed on PetAirapy's PA-260 Ultraviolet germicidal irradiation (UVGI) unit, and the PetAirapy PA-777, a portable six-part filtration air sanitization unit for use on pets with allergies, testing the disinfectant efficacy against a variety of animal and human pathogens transmissible through contaminated surfaces or air.

The game changing kill rates are previously unheard of in the pet industry.

Among the findings, verified three times, PetAirapy's proprietary UVGI technology wiped out 99.98% of Parvo in just 60 seconds. Identical results were confirmed for common pet pathogens such as canine influenza (H3N8), MRSA and Kennel Cough and Feline Calicivirus (FCV).

"Unlike inferior devices that use low output UV, the high output Germicidal Ultraviolet wavelength used in PetAirapy technology penetrates the cell membrane and decomposes the DNA of microorganisms. When cells are no longer able to circulate or reproduce, bacteria and viruses will die. PetAirapy is the only company in the pet industry that provides a commercial grade, high output UVGI solution," explains Annette Uda, CEO and founder of PetAirapy.

The testing was conducted by an independent laboratory Biological Consulting Services of North Florida, Inc. (BCS), a microbiological research and testing facility with close ties to the Center for Disease Control (CDC) and the EPA.

"The tested system from PetAirapy demonstrated excellent antibacterial and antiviral efficacy. The high output of UVGI tested ensures the heavy irradiation of any microorganisms and should effectively reduce and control the transmission of pathogens," says Dr. Lukasik, an international expert in microbial pollution and disinfection who oversaw the study.

Dr. Melissa Kennedy DVM, PH. D Assistant Professor for the Department of Comparative Medicine at the College of Veterinary Medicine reviewed PetAirapy's protocol used to test the irradiation product.

"The product performed exceedingly well, reducing viable pathogen levels to negligible or low levels, including Feline Calicivirus (FCV) and Parvo (CPV)," says Dr. Kennedy.

The revolutionary kill rates are made possible because of PetAirapy's proprietary UVGI technology, also known as Commercial grade UVGI, mandated to be installed in government facilities, and broadly used in hospitals. UVGI outperforms the UV found in inferior residential air cleaners.

"As the only provider of devices using commercial grade high output UVGI in the pet industry, we're tremendously proud to have a solution for both air and surface that will help combat Parvo, Kennel Cough, allergens and other pathogens that cause pet diseases in homes, animal shelters, animal laboratories, veterinary clinics, kennels, and wherever pets are housed," adds Annette Uda.

For more information please visit www.PetAirapy.com.

PetAirapy is a provider of products, services and solutions designed to eliminate viruses, bacteria and fungi and dramatically reduce the risk of infection. The company is headquarters in St. Charles, Illinois.

Contact Information

  • Media Contact:

    Annette Uda
    Phone: 630-377-0348
    Mail: Email Contact